がん診断におけるAI市場：コンポーネント、展開、がんタイプ、エンドユーザー別- 世界予測2024-2030年

がん診断におけるAI市場規模は2023年に2億2,038万米ドルと推定され、2024年には2億6,628万米ドルに達し、CAGR 21.52％で2030年には8億6,250万米ドルに達すると予測されます。

がん診断における人工知能（AI）には、がんの検出、診断、予測のために医療画像やデータを処理、分析、解釈するための高度なアルゴリズムとソフトウェアの使用が含まれます。これらのAI主導型システムは、機械学習や深層学習の機能を備えており、膨大な量の腫瘍学的データから学習し、時間の経過とともに精度と効率を向上させることができます。世界人口におけるがんの有病率の増加と個別化医療のニーズの高まりが、ヘルスケア分野におけるAIの採用を後押ししています。さらに、非侵襲的ながん診断への急激なシフトとともに、世界中のいくつかのがん検診プログラムでの採用が急増していることが、がん治療におけるAIの統合を後押ししています。しかし、AI統合がん治療の高コストと訓練を受けたがん専門医の不足が、がん診断市場におけるAIの拡大に影響を与えています。さらに、政府投資に支えられたがん診断の技術改善は、市場成長の有利な機会を生み出しています。

地域別インサイト

米国とカナダを含む米国地域では、早期発見と個別化医療が重視され、AIベースのがん診断への需要が高まっています。著名な研究機関や企業はAI研究に多額の投資を行っており、FDAなどの調査機関はAI診断ツールの承認を急いでいます。企業や学術機関によるAIの特許出願は、画像診断やゲノムデータ解析のための機械学習アルゴリズムの技術革新を反映しています。プライバシーや精度に関する懸念が払拭されれば、顧客はAIを活用したヘルスケア・サービスを一般的に受け入れています。EU諸国の多くは、政府のイニシアチブを通じて、ヘルスケア分野における包括的なAIの研究開発活動に取り組んでいます。同地域では、人口の高齢化とがん罹患率の増加により、がん診断におけるAIに対する顧客ニーズが高いです。顧客の購買行動については、欧州では厳しいGDPR規制に準拠した製品やサービスが好まれる傾向にあります。中東では、スマートヘルス技術に多額の投資が行われており、AIがん診断ツールの市場が拡大しています。APAC地域では、高齢化が消費者ニーズを牽引し、がん診断におけるAIの市場が拡大しています。APAC地域では、顧客はますます技術に精通し、AIヘルスケアソリューションに前向きになっており、また、政府によるAI研究の支援ががん診断におけるAIの急成長市場を確立しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、がん診断におけるAI市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront（F）、Pathfinder（P）、Niche（N）、Vital（V）に分類されます。

市場シェア分析

市場シェア分析は、がん診断におけるAI市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、がん診断におけるAI市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界人口におけるがんの罹患率
    • 世界中のいくつかのがん検診プログラムで採用が急増
    • 非侵襲的がん診断への急速な移行
  • 抑制要因
    • 高額な費用と訓練を受けた腫瘍医の不足
  • 機会
    • がん診断における技術的進歩
    • がん診断におけるAIの使用と治療に対する政府の投資
  • 課題
    • サイバー攻撃やデータ侵害に対する脆弱性
• 市場セグメンテーション分析
  • コンポーネント：大量テストセンターでは、エラーを最小限に抑えながら大規模なデータ処理を実行できる高度なハードウェアが好まれます。
  • がんの種類：脳腫瘍の複雑さと正確な腫瘍分類の必要性により、AIによる診断の重要性が高まっています。
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 がん診断におけるAI市場：コンポーネント別

• ハードウェア
• サービス
• ソフトウェア

第7章 がん診断におけるAI市場：展開別

• クラウド
• オンプレミス

第8章 がん診断におけるAI市場がんの種類別

• 脳腫瘍
• 乳がん
• 大腸がん
• 肺がん
• 前立腺がん
• 皮膚ガン

第9章 がん診断におけるAI市場：エンドユーザー別

• がんセンター
• 病院

第10章 南北アメリカのがん診断におけるAI市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん診断におけるAI市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん診断におけるAI市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • オウキン、MSDと提携しAIを活用したがん診断法を開発
  • ConcertAI、AIを活用した画像ソリューションを通じて精密腫瘍学を加速・変革するため、Cancer Centerとの契約を発表
  • ロシュは、がん診断の改善に役立つAI対応デジタル病理学ソリューションの導入を加速するためにIbexおよびAmazon Web Servicesと提携
• 戦略分析と提言

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. AI IN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. AI IN CANCER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 68. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 69. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 70. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 71. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 72. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 73. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 74. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 81. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 82. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 91. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 92. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 102. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 103. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 104. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 109. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 112. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 113. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 114. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 115. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 116. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 117. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 120. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 121. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 122. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 123. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 124. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 125. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 128. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 133. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 136. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 141. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 144. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 149. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 152. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 157. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 158. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 159. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 160. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 165. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 168. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 176. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 181. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 184. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 189. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 192. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 197. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 209. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 210. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 215. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 218. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 223. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 224. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 225. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 226. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 231. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 232. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 233. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 234. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 239. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 242. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 247. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 248. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 249. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 250. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 255. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 256. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 257. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 258. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 259. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 260. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 261. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 262. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 263. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 266. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 267. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 268. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 271. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 274. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 275. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 276. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 279. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 280. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 281. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 282. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 283. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 284. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 287. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 290. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 291. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 292. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 293. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 294. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 295. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 296. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 297. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 298. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 299. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 300. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 301. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 302. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 303. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 304. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 305. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 306. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 307. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 308. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 309. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 310. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 311. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 312. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 314. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 316. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 317. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 318. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 319. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 320. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 322. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 324. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 325. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 326. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 327. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 328. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 329. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 330. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 331. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
• TABLE 332. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
• TABLE 333. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 334. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 335. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 336. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 337. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
• TABLE 338. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
• TABLE 339. SWEDEN AI IN CANCER DIAGNOSTIC

[193 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.

Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.

Regional Insights

In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.

Market Insights

• Market Dynamics

The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Prevalence of cancer among the global population
  • Proliferating adoption in several cancer screening programs worldwide
  • Exponential shift towards non-invasive cancer diagnosis

• Market Restraints
  • High cost and shortage of trained oncologists

• Market Opportunities
  • Technological improvements in cancer diagnostics
  • Government investments in using AI in cancer diagnostics and treatments

• Market Challenges
  • Vulnerability to cyberattacks and data breaches
• Market Segmentation Analysis
  • Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
  • Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification

• Market Disruption Analysis
• Porter's Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer

Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]

ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions

ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]

Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses

F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Component
  • Hardware
  • Services
  • Software

• Deployment
  • Cloud
  • On-Premise

• Cancer Type
  • Brain Tumor
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer

• End-user
  • Cancer Centers
  • Hospitals

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancer among the global population
    • 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
    • 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and shortage of trained oncologists
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological improvements in cancer diagnostics
    • 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Vulnerability to cyberattacks and data breaches
• 5.2. Market Segmentation Analysis
  • 5.2.1. Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
  • 5.2.2. Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. AI in Cancer Diagnostics Market, by Component

• 6.1. Introduction
• 6.2. Hardware
• 6.3. Services
• 6.4. Software

7. AI in Cancer Diagnostics Market, by Deployment

• 7.1. Introduction
• 7.2. Cloud
• 7.3. On-Premise

8. AI in Cancer Diagnostics Market, by Cancer Type

• 8.1. Introduction
• 8.2. Brain Tumor
• 8.3. Breast Cancer
• 8.4. Colorectal Cancer
• 8.5. Lung Cancer
• 8.6. Prostate Cancer
• 8.7. Skin Cancer

9. AI in Cancer Diagnostics Market, by End-user

• 9.1. Introduction
• 9.2. Cancer Centers
• 9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
  • 13.3.2. ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
  • 13.3.3. Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio